Analyst Ratings For Affimed NV (NASDAQ:AFMD)
Today, Svb Leerink initiated coverage on Affimed NV (NASDAQ:AFMD) with a Outperform with a price target of $8.00.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Affimed NV (NASDAQ:AFMD) is Buy with a consensus target price of $5.2340 per share, a potential 27.97% upside.
Some recent analyst ratings include
- 3/28/2019-Affimed NV (NASDAQ:AFMD) has coverage initiated with a Outperform rating and $8.00 price target
- 3/28/2019-Affimed NV (NASDAQ:AFMD) has coverage initiated with a Outperform rating and $4.17 price target
- 8/28/2018-Affimed NV (NASDAQ:AFMD) gets upgraded to Buy by Jefferies Financial Group with a price target of $4.00
- 11/24/2017-Affimed NV (NASDAQ:AFMD) had its Hold rating reiterated by Oppenheimer
About Affimed NV (NASDAQ:AFMD)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, a NK-cell bispecific antibody targets EGFR-wild type represents a validated antigen expressed by various solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Recent Trading Activity for Affimed NV (NASDAQ:AFMD)
Shares of Affimed NV closed the previous trading session at 4,05 −0,12 2,88 % with 882690 shares trading hands.
